Should I Buy CNMD? CNMD 2026 Analysis

Should You Buy Conmed Corp (CNMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

37.400

1 Day change

0.24%

52 Week Range

74.700

Analysis Updated At

2026/01/28

CNMD is not a good buy right now for a beginner long-term investor who wants to deploy capital immediately. The stock is in a clear technical downtrend (bearish moving averages and weakening MACD), and the latest quarter shows profits and margins collapsing despite modest revenue growth. With analysts cutting price targets and no near-term positive news catalysts, the risk/reward is unfavorable at today’s price (~$38.65).

Technical Analysis

Trend: Bearish. The moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), which typically signals a sustained downtrend. Momentum: MACD histogram is -0.308 and negatively expanding, indicating downside momentum is strengthening. Overbought/oversold: RSI(6) is ~23.9, which is oversold (not neutral). This can support a short-term bounce, but oversold conditions can persist in downtrends. Key levels: Current price 38.65 is below S1 (39.11) and above S2 (38.03), meaning it’s trading in a weak area just above a lower support. Near-term resistance is the Pivot (40.86) then R1 (42.61). Pattern-based forward look (provided): Similar candlestick pattern stats imply slightly negative drift over the next week/month (about -0.43% next week, -0.64% next month). Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning: Open interest put-call ratio of 0.33 suggests more call OI than put OI (bullish-leaning positioning). Liquidity/conviction: Daily volume is extremely low (todays_volume=3; call volume 0), so the volume-based sentiment is not very reliable. Volatility: 30D IV ~52% vs historical vol ~36% (IV elevated). IV percentile ~69 suggests options are pricing relatively high uncertainty. Takeaway: OI leans bullish, but today’s option activity is too thin to treat as strong sentiment confirmation; elevated IV aligns with uncertainty into upcoming catalysts (earnings).

Technical Summary

Sell

Buy

Positive Catalysts

is oversold (~23.9), which can support a short-term bounce even within a downtrend.
on 2026-01-28 after hours could reset expectations if margins/profitability improve meaningfully.

Neutral/Negative Catalysts

Downtrend intact: Bearish MA stack and worsening MACD indicate sellers remain in control; price is below a key support (S1 ~39.11).
Fundamentals deterioration (latest quarter): Sharp YoY collapse in net income and EPS and a notable gross margin decline, despite revenue growth.
Analyst pressure: Multiple price target cuts recently (even where ratings stayed Neutral/Overweight), suggesting reduced confidence in near-term upside.
Low visibility into near-term drivers: No positive news flow in the last week; catalyst risk concentrates around earnings.
Influential trading: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trends.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue: 337.93M, up +6.70% YoY (top-line growth is positive). Profitability: Net income 2.86M, down -94.16% YoY; EPS 0.09, down -94.27% YoY. Margins: Gross margin 49.16%, down -13.02% YoY. Interpretation: Growth is being achieved without translating into profits—profitability and margin trends are the main concern for long-term investors until they stabilize and recover.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Analysts have been cutting price targets over the last few months. - 2025-12-07 BofA: Neutral; PT cut to $52 from $65 after decision to exit gastroenterology lines (margin accretive but EPS dilutive in 2026). - 2025-11-06 Piper Sandler: Overweight; PT cut to $55 from $68 after in-line Q3 and slightly lower EPS outlook. - 2025-11-06 JPMorgan: Neutral; PT cut to $52 from $58 after “slow and steady” improvements. Wall Street pros: Some see operational improvements and potential margin mix benefits. Wall Street cons: Broad PT cuts and Neutral stances imply limited near-term upside and concern about earnings power (including 2026 dilution from portfolio changes).

5 Analyst Rating

Wall Street analysts forecast CNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNMD is 50 USD with a low forecast of 41 USD and a high forecast of 55 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

Current: 37.310

Low

Averages

High

Current: 37.310

Low

Averages

High

BofA

Neutral

downgrade

$65 -> $52

AI Analysis

2025-12-07

Reason

BofA

Price Target

$65 -> $52

AI Analysis

2025-12-07

downgrade

Neutral

Reason

BofA lowered the firm's price target on Conmed to $52 from $65 and keeps a Neutral rating on the shares after the company said it will exit its gastroenterology product lines. The exit is accretive to gross margins but dilutive to earnings in 2026, the analyst tells investors in a research note.

Piper Sandler

Matt O'Brien

Overweight

downgrade

$68 -> $55

2025-11-06

Reason

Piper Sandler

Matt O'Brien

Price Target

$68 -> $55

2025-11-06

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Conmed to $55 from $68 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that were roughly in-line with its estimates on the top-and-bottom line. Management essentially kept its revenue guidance for the year unchanged but did lower EPS by three cents, Piper adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNMD

Unlock Now

CNMD Should I Buy

CNMD Should I Buy

Should You Buy Conmed Corp (CNMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch